Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Business Insights | The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality being the ideological basis of these welfare states, a significant public commitment exists towards ensuring access to high quality health care for all citizens. Whilst doctors make the choice of the medication, the authorities pay the cost of these drugs, insuring citizens against large drug expenses. The public sector bears this cost of pharmaceuticals either directly through hospitals or by providing reimbursement to patients. Pharmaceutical price regulation comes into play not just at the point of sale to the final consumer but at all parts of the distribution chain. Price regulation also varies depending on whether the drug is a patent protected prescription drug or a prescription drug facing generic competition or a non-prescription drug. The prevalence of parallel trade further shapes the dynamics of the pharmaceutical market in the Scandinavian region, while also affecting the states’ expenditure on health. Incentives existing for patients and pharmacists to switch to a lower priced product drive savings from parallel trade. In Sweden for instance, the state is able to generate significant savings as parallel imports are considered substitutable products under the generic substitution policy and pharmacists are required to always dispense the cheapest of alternative products.

Published: March 2009 - Europe.
Table of Contents
Price: $3,835.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions